Latest Revenue Forecast News

Monadelphous Group Limited reported a robust FY25 with record contract wins and a 30% revenue surge, setting the stage for continued growth in FY26. The company’s strategic acquisitions and energy transition focus underpin its optimistic outlook.

Atturra Limited reported a robust 24% increase in both revenue and underlying EBITDA for FY25, propelled by its cloud platform, AI innovations, and defence sector contracts. The company forecasts continued momentum into FY26 with ambitious growth targets.

SKS Technologies reported a remarkable doubling of profit in FY25, driven by strong organic growth and a strategic acquisition that positions it for rapid expansion in Australia's largest data centre market.

EVZ Limited has issued earnings guidance for the first half of FY2026, forecasting revenue between $60 million and $65 million and a notable rise in EBITDA, reflecting operational improvements.

The a2 Milk Company has raised its FY26 revenue guidance, citing stronger-than-expected performance in key product categories and favourable currency movements. The company anticipates solid earnings growth and robust cash flow conversion.

SKS Technologies has landed its largest data centre contract yet, a $130 million project in Melbourne, lifting its total work on hand to $304 million and prompting an upward revision of its FY26 revenue guidance.

SportsHero has officially launched its HeroPlay mobile gaming platform in Indonesia through a partnership with Indosat Ooredoo Hutchison, offering over 600 instantly playable HTML5 games to nearly 99 million potential users.

Acusensus Limited has raised its FY26 revenue guidance to $83-$87 million, driven by significant new contracts in the US and New Zealand and expansions in Australia. This upgrade signals strong momentum in the company’s AI-powered road safety enforcement business.

Wagners Holding Company Limited reported a strong FY25 with profits more than doubling, driven by robust construction demand in Southeast Queensland and growth in composite fibre technologies. The company raised $30 million to expand its concrete plants and composite production capacity, positioning for further growth in FY26.

Monadelphous Group Limited has raised its revenue guidance for 2025, buoyed by strong contract awards and elevated activity across its engineering and construction divisions.

Immuron Limited has secured FDA approval for its IMM-529 Investigational New Drug application, clearing the way for a Phase 2 clinical trial targeting Clostridioides difficile infection. This milestone marks a significant step forward for a novel oral antibody therapy addressing a critical infectious disease with high recurrence rates.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.